Anti-GM1 antibodies in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with intravenous immunoglobulin (IVIg).
Patients with chronic inflammatory demyelinating polyneuropathy (CIDP) and with a chronic polyneuropathy (non-CIDP) were studied for the presence of anti-GM1 antibodies. In pretreatment sera of CIDP patients, we found IgG anti-GM1 antibodies in 23%, IgM in 7%, and IgA in 14%. Predominantly motor involvement was associated with IgG and IgM anti-GM1 antibodies in CIDP patients (P = 0.002). Improvement after intravenous immunoglobulin (IVIg) therapy was not associated with anti-GM1 antibody titer before or after treatment. Anti-GM1 antibody titers before onset of treatment was not related to poor clinical outcome, although large clinical improvements after IVIg therapy were observed less often (P = 0.057) in patients with high titer anti-GM1 antibodies before treatment.
van Schaik
I N
IN
Department of Immunohematology, University Hospital Leiden, The Netherlands.
Vermeulen
M
M
van Doorn
P A
PA
Brand
A
A
D000200:Action Potentials; D000906:Antibodies / Q000032:analysis*; D002908:Chronic Disease; D003711:Demyelinating Diseases / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy; D005677:G(M1) Ganglioside / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous; D009068:Movement / Q000502:physiology; D011115:Polyneuropathies / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy; D012677:Sensation / Q000502:physiology
D000906:Antibodies; D016756:Immunoglobulins, Intravenous; D005677:G(M1) Ganglioside